MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$317,165K
Net cash provided by
(used in) financing...
$317,579K
Effect of foreign
exchange rate changes on...
$1K
Net increase
(decrease) in cash and cash...
$187,506K
Canceled cashflow
$130,074K
Maturities of
available-for-sale debt securities
$25,059K
Equity-based compensation
$2,015K
Accrued expenses and
other current...
$1,568K
Accounts payable
$550K
Non-cash lease expense
-$160K
Depreciation and
amortization
$75K
Net cash (used in)
provided by investing...
-$107,437K
Net cash used in
operating activities
-$22,637K
Canceled cashflow
$25,059K
Canceled cashflow
$4,368K
Purchases of
available-for-sale debt securities
$132,473K
Net loss
-$24,150K
Purchases of property and
equipment
$23K
Accretion of discount on
available-for-sale debt securities
$1,319K
Other non-current
assets
$739K
Prepaid expenses and
other current assets
$638K
Operating lease
liabilities
-$159K
Back
Back
Cash Flow
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)
source: myfinsight.com